Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL +0.41%74 Forward PE Ratio is 12.00 as of Aug. 27, 2026. GuruFocus rates BKK:HL with a GF Score™ of 74/100 and a GF Value™ of ฿9.96 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 316 Healthcare Providers & Services companies, Healthlead PCL ranks better than 78.48% on this metric.
Healthlead PCL (BKK:HL) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Healthlead PCL Forward PE Ratio Related Terms
Healthlead PCL Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healthlead PCL Forward PE Ratio Chart
Healthlead PCL Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
27.57
17.32
Healthlead PCL Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
27.57
17.57
18.92
18.54
17.32
15.12
13.41
Healthlead PCL Forward PE Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, Healthlead PCL's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Healthlead PCL (BKK:HL) has a Forward PE Ratio of 12.00 as of Aug. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Healthlead PCL and its competitors. According to the industry distribution chart, Healthlead PCL ranks #68 out of 316 companies in the Healthcare Providers & Services industry, placing it in the top 21.5%.
Is Healthlead PCL's Forward PE Ratio too high?
Healthlead PCL's current Forward PE Ratio is 12.00. The Healthcare Providers & Services industry median Forward PE Ratio is 19.26. Healthlead PCL's value of 12.00 is 37.7% below this industry median. Based on the distribution chart, Healthlead PCL ranks #68 out of 316 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Healthlead PCL has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's Forward PE Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #68 out of 316 companies for Forward PE Ratio. This places Healthlead PCL in the top 22% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 19.26. Healthlead PCL's value of 12.00 is 37.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 19.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current Forward PE Ratio of 12.00 is 37.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 19.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current Forward PE Ratio is 12.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿9.96, compared to a current price of ฿4.92 — trading 50.6% below its estimated fair value. The current Forward PE Ratio is 12.00 and 37.7% below the Healthcare Providers & Services industry median of 19.26. Healthlead PCL's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current Forward PE Ratio is 12.00 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿4.92 is trading 50.6% below its estimated GF Value™ of ฿9.96.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
Forward PE Ratio: 12.00
GF Value™: ฿9.96 vs. price of ฿4.92 (50.6% below fair value)
Industry Position: 37.7% below the Healthcare Providers & Services median (#68 of 316)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
74GF Score
Get the complete analysis for BKK:HL
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
